ArticlePET clinics2022
Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).
Article in PET clinics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 56 citations in OpenAlex.
- Advances in First-Line Treatment of Classical Hodgkin Lymphoma in the Era of Novel Agents.Journal of clinical medicine · 2026Review
- Global and regional accuracy of deep learning-based tumor segmentation from whole-body [EJNMMI research · 2025Article
- Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma withCurrent oncology (Toronto, Ont.) · 2025Article
- Review
- Semi-supervised learning towards automated segmentation of PET images with limited annotations: application to lymphoma patients.Physical and engineering sciences in medicine · 2024Article
- TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images - a multi-center generalizability analysis.European journal of nuclear medicine and molecular imaging · 2024Article
- PrecisionLymphoNet: Advancing Malignant Lymphoma Diagnosis via Ensemble Transfer Learning with CNNs.Diagnostics (Basel, Switzerland) · 2024Article
- Empowering PET: harnessing deep learning for improved clinical insight.European radiology experimental · 2024Review
- Deep learning for [The Lancet. Digital health · 2024Article
- A whole-body diffusion MRI normal atlas: development, evaluation and initial use.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Radiomics predictive modeling from dual-time-point FDG PET KEJNMMI research · 2023Article
- A Guide to Cross-Validation for Artificial Intelligence in Medical Imaging.Radiology. Artificial intelligence · 2023Review
- Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.Blood research · 2022Review
- Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Malignant lymphomas are a family of heterogenous disorders caused by clonal proliferation of lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.